+

WO1998024912A3 - Recombinant plague vaccine - Google Patents

Recombinant plague vaccine Download PDF

Info

Publication number
WO1998024912A3
WO1998024912A3 PCT/US1997/022617 US9722617W WO9824912A3 WO 1998024912 A3 WO1998024912 A3 WO 1998024912A3 US 9722617 W US9722617 W US 9722617W WO 9824912 A3 WO9824912 A3 WO 9824912A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant
present
cells
viruses
molecules
Prior art date
Application number
PCT/US1997/022617
Other languages
French (fr)
Other versions
WO1998024912A2 (en
Inventor
Elizabeth J Haanes
Rex E Thomas
Jorge E Osorio
Original Assignee
Heska Corp
Elizabeth J Haanes
Rex E Thomas
Jorge E Osorio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heska Corp, Elizabeth J Haanes, Rex E Thomas, Jorge E Osorio filed Critical Heska Corp
Priority to AU55979/98A priority Critical patent/AU5597998A/en
Publication of WO1998024912A2 publication Critical patent/WO1998024912A2/en
Publication of WO1998024912A3 publication Critical patent/WO1998024912A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a recombinant vaccine to protect animals against plague. More particularly, the invention includes recombinant molecules containing isolated nucleic acid molecules that encode proteins from Yersinia, Pasteurella, or Francisella bacteria expressed in eukaryotic cells. In one embodiment, the recombinant molecule is an animal virus genome; in another embodiment the recombinant molecule is a recombinant plasmid. The present invention also includes recombinant viruses comprising a recombinant animal virus genome and recombinant cells comprising either a recombinant virus or a recombinant plasmid. The present invention further includes therapeutic compositions comprising such recombinant molecules, viruses and cells, as well as methods to protect animals from plague.
PCT/US1997/022617 1996-12-04 1997-12-04 Recombinant plague vaccine WO1998024912A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55979/98A AU5597998A (en) 1996-12-04 1997-12-04 Recombinant plague vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76711596A 1996-12-04 1996-12-04
US08/767,115 1996-12-04

Publications (2)

Publication Number Publication Date
WO1998024912A2 WO1998024912A2 (en) 1998-06-11
WO1998024912A3 true WO1998024912A3 (en) 1998-09-11

Family

ID=25078527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/022617 WO1998024912A2 (en) 1996-12-04 1997-12-04 Recombinant plague vaccine

Country Status (2)

Country Link
AU (1) AU5597998A (en)
WO (1) WO1998024912A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563004B2 (en) 2005-01-21 2013-10-22 Epitopix Llc Yersinia spp. polypeptides and methods of use

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1394500A (en) * 1998-11-18 2000-06-05 Innature Limited Product
US7344718B2 (en) 2003-01-31 2008-03-18 University Of North Dakota Yersinia species compositions
JP2011514881A (en) 2007-11-09 2011-05-12 ザ ソルク インスティテュート フォー バイオロジカル スタディーズ Use of TAM receptor inhibitors as immunopotentiators and use of TAM activators as immunosuppressants
WO2012178078A2 (en) 2011-06-22 2012-12-27 University Of North Dakota Use of yscf, truncated yscf and yscf homologs as adjuvants
US9328149B2 (en) * 2013-07-12 2016-05-03 The Catholic University Of America Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines
CN114560932B (en) * 2022-02-18 2023-09-12 中国人民解放军军事科学院军事医学研究院 Plague neutralizing antibody and application thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007140A1 (en) * 1988-02-05 1989-08-10 Commonwealth Scientific And Industrial Research Or Gene expression system (particularly for rotavirus vp7 protein) involving a foreign signal peptide and optionally a transmembrane anchor sequence
WO1990002484A1 (en) * 1988-09-06 1990-03-22 Washington University Oral immunization by transgenic plants
WO1993001284A1 (en) * 1991-07-09 1993-01-21 Cornell Research Foundation, Inc. Recombinant viral vaccine
WO1993008290A1 (en) * 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5266313A (en) * 1987-02-03 1993-11-30 The United States Of America As Represented By The Department Of Health And Human Services Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
WO1994024296A2 (en) * 1993-04-19 1994-10-27 University Of Saskatchewan Recombinant bovine herpesvirus type 1 vaccines
EP0652287A2 (en) * 1993-09-22 1995-05-10 American Home Products Corporation Poxviral vectors and their use as a vaccine against feline infectious peritonitis virus disease
WO1995018231A1 (en) * 1993-12-24 1995-07-06 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Vaccine compositions comprising live bacterial vectors for protection against yersinia pestis injection
WO1996021356A1 (en) * 1995-01-13 1996-07-18 Vanderbilt University Methods and compositions for inducing mucosal immune responses
WO1996028551A1 (en) * 1995-03-13 1996-09-19 The Secretary Of State For Defence Vaccines for plague

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266313A (en) * 1987-02-03 1993-11-30 The United States Of America As Represented By The Department Of Health And Human Services Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
WO1989007140A1 (en) * 1988-02-05 1989-08-10 Commonwealth Scientific And Industrial Research Or Gene expression system (particularly for rotavirus vp7 protein) involving a foreign signal peptide and optionally a transmembrane anchor sequence
WO1990002484A1 (en) * 1988-09-06 1990-03-22 Washington University Oral immunization by transgenic plants
WO1993001284A1 (en) * 1991-07-09 1993-01-21 Cornell Research Foundation, Inc. Recombinant viral vaccine
WO1993008290A1 (en) * 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
WO1994024296A2 (en) * 1993-04-19 1994-10-27 University Of Saskatchewan Recombinant bovine herpesvirus type 1 vaccines
EP0652287A2 (en) * 1993-09-22 1995-05-10 American Home Products Corporation Poxviral vectors and their use as a vaccine against feline infectious peritonitis virus disease
WO1995018231A1 (en) * 1993-12-24 1995-07-06 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Vaccine compositions comprising live bacterial vectors for protection against yersinia pestis injection
WO1996021356A1 (en) * 1995-01-13 1996-07-18 Vanderbilt University Methods and compositions for inducing mucosal immune responses
WO1996028551A1 (en) * 1995-03-13 1996-09-19 The Secretary Of State For Defence Vaccines for plague

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAMSON E.D. ET AL.: "A new improved sub-unit vaccine for plague: the basis of protection", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, vol. 12, 1 January 1995 (1995-01-01), pages 223 - 230, XP000573083 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563004B2 (en) 2005-01-21 2013-10-22 Epitopix Llc Yersinia spp. polypeptides and methods of use
US9085612B2 (en) 2005-01-21 2015-07-21 Epitopix, Llc Yersinia spp. polypeptides and methods of use
US9085613B2 (en) 2005-01-21 2015-07-21 Epitopix, Llc Yersinia spp. polypeptides and methods of use
US9109018B2 (en) 2005-01-21 2015-08-18 Epitopix, Llc Yersinia spp. polypeptides and methods of use
US9221899B2 (en) 2005-01-21 2015-12-29 Epitopix Llc Yersinia spp. polypeptides and methods of use
US9352029B2 (en) 2005-01-21 2016-05-31 Epitopix, Llc Yersinia spp. polypeptides and methods of use

Also Published As

Publication number Publication date
WO1998024912A2 (en) 1998-06-11
AU5597998A (en) 1998-06-29

Similar Documents

Publication Publication Date Title
DK1783225T3 (en) Structural protein from AAV, its preparation and use
WO1999020766A3 (en) NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
BR9610511B1 (en) DNA constructs useful in gene therapy comprising at least one nucleic sequence of interest and pharmaceutical composition.
EP0910406A4 (en) RECOMBINANT CANINE HERPESVIRUS
EP0331939A3 (en) Method and compositions for conferring resistance to retroviral infection
DE59410380D1 (en) ENDOSOMOLYTICALLY EFFECTIVE PARTICLES
EP2039769A3 (en) Antimicrobial peptides and methods of use
NO962791L (en) Preparations containing nucleic acids, their preparation and use
CA2339791A1 (en) Methods and compositions for cloning nucleic acid molecules
WO2001079442A3 (en) Albumin fusion proteins
WO2002097048A3 (en) ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
GB2396814A (en) Vaccine
AUPN477695A0 (en) Gene therapy
NO983946L (en) Parapox viruses containing foreign DNA, preparation and use thereof in vaccines
WO2000053776A3 (en) Human kallikrein-like genes
WO2002096939A3 (en) Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
WO1998024912A3 (en) Recombinant plague vaccine
DE69504808D1 (en) CORTICOTROPIN RELEASING RECEPTORS OF FACTOR 2
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO1995032297B1 (en) Novel chromosome fragment and its use as a vector
CA2245545A1 (en) Vaccines against varicella zoster virus gene 63 product
EP0256677A3 (en) Pseudorabies virus recombinants and their use in the production of proteins
WO1999057284A3 (en) Attenuated influenza viruses
WO2000066743A3 (en) Viral expression vectors
HUP9904201A1 (en) Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09319290

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载